Glaxo Wellcome Zovirax holds onto 53% of acyclovir new Rxs in first full month of generics -- Scott-Levin.
GLAXO ZOVIRAX HELD 53% SHARE OF NEW ACYCLOVIR Rxs IN MAY, the first full month in which generics of the herpes therapy were marketed, according to Scott-Levin data. Glaxo Wellcome's patent for acyclovir expired April 23; 17 ANDAs were approved that week ("The Pink Sheet" May 5, T&G-4). Generic acyclovir captured 2% of new acyclovir prescriptions in April.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth